Table 4 Cox multivariable analysis for breast cancer-specific survival (BCSS) in the BCCA cohorta
From: αB-crystallin expression in breast cancer is associated with brain metastasis
Variables | HR | 95% CI | P-value |
|---|---|---|---|
Age at diagnosis, years | 0.022 | ||
>55 (n=1,790) | 1 | ||
<40 (n=239) | 1.2 | 0.91–1.5 | 0.22 |
40–55 (n=946) | 0.87 | 0.72–1.0 | 0.12 |
Grade | 1.5 | 1.3–1.8 | |
3 (n=1,643) vs. 2/1 (n=1,332) | <0.0001 | ||
Nodal status | 2.6 | 2.1–3.0 | |
Positive (n=1,686) vs. negative (n=1,289) | <0.0001 | ||
Tumor size, cm | <0.0001 | ||
⩽2 (n=1,545) | 1 | ||
2–5 (n=1,290) | 1.6 | 1.4–1.8 | <0.0001 |
>5 (n=140) | 2.2 | 1.6–2.8 | <0.0001 |
Initial systemic therapy | |||
Any hormonal (n=1,128) vs. none (n=1,847) | 0.88 | 0.74–1.1 | 0.16 |
Any chemo (n=773) vs. none (n=2,202) | 0.86 | 0.69–1.1 | 0.14 |
Biomarkers | |||
ER-positive (n=2,148) vs. negative (n=827) | 0.89 | 0.75–1.1 | 0.18 |
HER2-positive (n=414) vs. negative (n=2,561) | 1.4 | 1.2–1.7 | <0.0001 |
αB-crystallin-positive (n=332) vs. negative (n=2,643) | 1.3 | 1.1–1.6 | 0.014 |
